Confocal Microscopy Predicts the Risk of Recurrence and Malignant Transformation of Mucocutaneous Neurofibromas in NF-1: An Observational Study

From 2005 to 2010, 20 consecutive patients with fully manifested neurofibromatosis type 1 (NF1) underwent elective neurofibroma resection at our institution (Departments of Plastic Surgery and of Odontostomatology). Specimens were photographed under optical microscope and confocal laser scanning microscopy (CLSM) with ultra-high accuracy of detail, including depth of field. Patients were followed up for a minimum of 4 years and up to a maximum of 12 years, postsurgery. While all nonrecurring lesions showed intense fluorescence, six of the seven lesions with absence of fluorescence under CLSM recurred at a mean of 5.5 years after surgical excision. Among the re-excised lesions, 3 were diagnosed as malignant at the subsequent removal. Despite the limitation of a small cohort, CLSM appears to be a simple and low-cost technique to differentiate forms of neurofibromas with low and high risk of recurrence and malignant degeneration.

[1]  R. Sciot,et al.  The characteristics of 76 atypical neurofibromas as precursors to neurofibromatosis 1 associated malignant peripheral nerve sheath tumors , 2018, Neuro-oncology.

[2]  B. Korf,et al.  Cutaneous neurofibromas in Neurofibromatosis type I: a quantitative natural history study , 2018, Orphanet Journal of Rare Diseases.

[3]  Á. Nagy,et al.  [Pathogenic alterations within the neurofibromin gene in various cancers]. , 2017, Magyar Onkológia.

[4]  D. Evans,et al.  Increased risk of breast cancer in neurofibromatosis type 1: current insights , 2017, Breast cancer.

[5]  D. Cooper,et al.  The NF1 somatic mutational landscape in sporadic human cancers , 2017, Human Genomics.

[6]  K. Busam,et al.  The NF1 gene in tumor syndromes and melanoma , 2017, Laboratory Investigation.

[7]  C. Romano,et al.  Mutation spectrum of NF1 gene in Italian patients with neurofibromatosis type 1 using Ion Torrent PGM™ platform. , 2017, European journal of medical genetics.

[8]  D. Gutmann,et al.  Dissecting Clinical Heterogeneity in Neurofibromatosis Type 1. , 2017, Annual review of pathology.

[9]  C. Liao,et al.  The role of nerve microenvironment for neurofibroma development , 2016, Oncotarget.

[10]  N. Ratner,et al.  A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor , 2015, Nature Reviews Cancer.

[11]  M. Guida,et al.  High activity of sequential low dose chemo-modulating Temozolomide in combination with Fotemustine in metastatic melanoma. A feasibility study , 2010, Journal of Translational Medicine.

[12]  M. Mahalingam NF1 and Neurofibromin: Emerging Players in the Genetic Landscape of Desmoplastic Melanoma , 2017, Advances in anatomic pathology.